九州通医药集团股份有限公司 会计师事务所选聘制度 第一章 总 则 （四）具有完成审计任务和确保审计质量的注册会计师； 第一条 为规范九州通医药集团股份有限公司（以下简称"公司"）选聘（包 括新聘、续聘、变更）会计师事务所的行为，切实维护股东利益，提高审计工作 和财务信息的质量，依据《公司法》《证券法》《国有企业、上市公司选聘会计师 事务所管理办法》等法律、行政法规、部门规章、规范性文件和《公司章程》的 有关规定，结合公司实际情况，制定本制度。 第二条 公司选聘会计师事务所对财务会计报告发表审计意见、出具审计报 告，需遵照本制度的规定。公司聘任会计师事务所从事除财务会计报告审计之外 的其他法定审计业务的，可以比照本制度执行。 第三条 公司聘用或解聘会计师事务所，应当由财务与审计委员会审议同意 后，提交董事会审议，并由股东会决定。公司不得在董事会、股东会审议批准前 聘请会计师事务所开展审计业务。 第四条 公司控股股东、实际控制人不得向公司指定会计师事务所，不得干 预财务与审计委员会、董事会及股东会独立履行职责。 第二章 会计师事务所选聘条件 第五条 公司选聘的会计师事务所应当具备下列条件： （一）具备中国证券监督 ...

证券代码：600998 证券简称：九州通 公告编号：临 2024-021 九州通医药集团股份有限公司 关于 2023 年度利润分配及资本公积金转增股本预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）公司拟以资本公积金向全体股东每10股转增2.90股，不送红股。截至 2024年3月31日，公司总股本3,908,891,654股，以此计算合计转增1,133,578,580 1 股；本次转股后，公司总股本将增加至5,042,470,234股。 如在本公告披露之日起至实施权益分派股权登记日期间公司总股本发生变 动的，公司拟维持每股分配及转增比例不变，相应调整分配及转增总额。 二、公司履行的决策程序 利润分配及转增比例：每10股派发现金红利2.50元（含税），每10股转 增2.90股，不送红股； 本次利润分配及资本公积金转增股本以实施权益分派股权登记日登记的 总股本为基数，具体日期将在权益分派实施公告中明确； 如在股权登记日前公司总股本发生变动，公司拟维持每股分配及转增比 例不变，相应调整分配及转增总额 ...

九州通医药集团股份有限公司董事会 关于2023年度独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指 引第 1 号—规范运作》等法律法规、规范性文件的要求，九州通医药集团股份有 限公司（以下简称"公司"）董事会就公司在任独立董事曾湘泉先生、汤谷良先 生、艾华先生、陆银娣女士的独立性情况进行评估并出具如下专项意见： 经核查上述人员的任职经历以及其签署的相关自查文件，公司上述在任独立 董事未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任 何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客 观判断的关系，符合《上市公司独立董事管理办法》《上海证券交易所上市公司 自律监管指引第 1 号—规范运作》等相关规则中对独立董事应具有独立性的相 关要求。 九州通医药集团股份有限公司董事会 2024 年 4 月 27 日 ...

九州通医药集团股份有限公司 独立董事专门会议工作制度 第一章 总 则 第一条 为了进一步完善九州通医药集团股份有限公司（以下简称"公司"） 法人治理结构，促进公司规范运作，依据《公司法》《证券法》《上市公司独立 董事管理办法》等相关法律法规、规范性文件以及《公司章程》的有关规定，结 合公司实际情况，制定本制度。 第二条 独立董事专门会议是独立董事的专门工作机构，按照公司《独立董 事制度》及本工作制度的规定履行职责。 第二章 议事规则 第三条 公司根据需要召开独立董事专门会议，原则上应当至少提前二日通 知全体独立董事。如情况紧急，需要尽快召开独立董事专门会议，经全体独立董 事一致同意，可不受前述通知时限限制。 第四条 会议通知包括以下内容： （一）会议日期和地点； （四）发出通知的日期。 第五条 独立董事专门会议应当由过半数独立董事共同推举一名独立董事 召集和主持；召集人不履职或者不能履职时，两名及以上独立董事可以自行召集 并推举一名代表主持。 第六条 独立董事专门会议在保证全体参会独立董事能够充分沟通并表达意 见的前提下，可以采用现场、视频、电话、邮件、传签或者其他方式召开。 第七条 独立董事专门会议应当由半 ...

九州通医药集团股份有限公司 2023 年度董事会工作报告 2023 年，九州通医药集团股份有限公司（以下简称"公司"或"九州通"） 坚持高质量发展理念，不再片面追求销售收入规模的扩张，而是更加注重经营管 理质量的提升，在持续巩固医药分销业务竞争优势的同时，逐步向医药 CSO、医 药新零售、医药工业等多业态转型升级，并通过数字化、平台化、互联网化建设， 赋能公司业务变革及管理创新；同时，公司治理水平不断提升，公司董事会严格 按照《公司法》《证券法》以及《公司章程》等相关规定，积极开展董事会各项 工作，贯彻落实股东大会的各项决议，保障了公司规范运作和可持续健康发展。 一、2023 年公司重点工作成果 2023 年，公司全力拓展高质量业务，盈利能力不断提升。公司营业收入再 创历史新高，达到 1,501.40 亿元，较上年同期增长 6.92%；扣非归母净利润达 19.60 亿元，较上年同期增长 13.06%，扣非归母净利润的增长快于营业收入的增 长；经营活动现金流再创新高，全年净额达 47.48 亿元，较上年同期增长 19.10%。 在行业的支付环境没有明显改善的情况下，公司的应收账款周转天数为 63 天， 比上年缩 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 40,472,147,237.18, representing a decrease of 3.85% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 537,675,138.46, down 4.19% year-on-year[3]. - Total revenue for Q1 2024 was CNY 40,472,147,237.18, a decrease of 3.9% compared to CNY 42,092,541,357.00 in Q1 2023[19]. - Net profit for Q1 2024 was CNY 542,165,921.17, a decrease from CNY 598,440,511.62 in Q1 2023, highlighting challenges in profitability[20]. - The total comprehensive income attributable to shareholders of the parent company for Q1 2024 was approximately ¥545.45 million, compared to ¥556.46 million in Q1 2023, reflecting a decrease of about 2%[21]. Cash Flow - The net cash flow from operating activities was negative at CNY -3,653,621,916.00, a decline of 20.92% compared to the previous year[3]. - The cash flow from operating activities for Q1 2024 was approximately -¥3.65 billion, worsening from -¥3.02 billion in Q1 2023[22]. - Cash inflow from operating activities totaled approximately ¥34.28 billion in Q1 2024, slightly up from ¥34.09 billion in Q1 2023[22]. - Cash outflow from operating activities increased to approximately ¥37.93 billion in Q1 2024, compared to ¥37.11 billion in Q1 2023[22]. - The net cash flow from investing activities for Q1 2024 was approximately -¥328.32 million, compared to -¥177.13 million in Q1 2023, indicating a larger outflow[23]. - The net cash flow from financing activities for Q1 2024 was approximately ¥1.50 billion, an increase from ¥1.46 billion in Q1 2023[23]. - The total cash and cash equivalents at the end of Q1 2024 stood at approximately ¥6.33 billion, up from ¥5.92 billion at the end of Q1 2023[23]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 97,241,243,539.77, an increase of 4.80% from the end of the previous year[4]. - Total assets increased to CNY 97,241,243,539.77 in Q1 2024, up from CNY 92,789,102,474.22 in Q1 2023, showing growth in the asset base[19]. - Non-current liabilities decreased to CNY 2,926,568,600.42 in Q1 2024 from CNY 3,246,241,583.19 in Q1 2023, indicating improved financial stability[19]. - The total equity increased to CNY 30,860,040,609.41 in Q1 2024 from CNY 29,476,998,176.43 in Q1 2023, indicating a stronger equity position[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,456[10]. - The top shareholder, Shanghai Hongkang Industrial Investment Co., Ltd., held 21.58% of the shares[10]. - The net profit attributable to shareholders of the parent company for Q1 2024 was approximately ¥537.68 million, a decrease from ¥561.17 million in Q1 2023, representing a decline of about 4.2%[21]. Operational Highlights - Accounts receivable increased by 50.17% due to expanded sales and increased customer debts[8]. - The company experienced a significant decrease of 85.35% in net cash flow from investing activities compared to the previous year[8]. - The company plans to establish an artificial intelligence joint laboratory with Peking University to enhance its digital management and supply chain capabilities[13]. - As of the end of Q1 2024, the number of direct and franchise pharmacies under the company reached 21,192, supporting its expansion strategy[14]. - The company launched a digital comprehensive service platform for the pharmaceutical supply chain in Hubei, which is the first provincial-level platform in the region[14]. - The company is actively promoting its "ten thousand store franchise" plan to enhance its market presence and competitiveness[14]. Cost and Investment - Total operating costs for Q1 2024 were CNY 39,678,052,125.51, down from CNY 41,206,285,361.96 in Q1 2023, reflecting a cost reduction strategy[20]. - R&D expenses increased to CNY 44,253,731.42 in Q1 2024, compared to CNY 38,919,048.20 in Q1 2023, indicating a focus on innovation[20]. - The company reported a 41.52% decrease in investment income, primarily due to reduced investment returns from subsidiaries[8]. - The company reported a total of RMB 1,184,170,808.49 in investment properties, up from RMB 1,167,435,291.46, indicating an increase of about 1.43%[16]. - The company’s long-term equity investments increased to RMB 1,997,215,462.35 from RMB 1,877,764,921.20, reflecting a growth of approximately 6.38%[16].

Financial Performance - Company's operating revenue reached a historical high of 150.14 billion yuan, a year-on-year increase of 6.92%[2] - Non-GAAP net profit attributable to the parent company was 1.96 billion yuan, a year-on-year increase of 13.06%[2] - Operating cash flow reached a record high of 4.748 billion yuan, a year-on-year increase of 19.10%[2] - Revenue for 2023 reached 150.14 billion RMB, a 6.92% increase compared to 2022[27] - Net profit attributable to shareholders in 2023 was 2.17 billion RMB, up 4.27% year-over-year[27] - Operating cash flow increased by 19.10% to 4.75 billion RMB in 2023[27] - Total assets grew by 0.52% to 92.79 billion RMB at the end of 2023[27] - Basic earnings per share rose 7.84% to 0.55 RMB in 2023[28] - Weighted average return on equity (ROE) increased by 0.06 percentage points to 9.04% in 2023[28] - The company achieved operating revenue of 150.14 billion yuan, a year-on-year increase of 6.92%, and net profit attributable to the parent company of 2.174 billion yuan, a year-on-year increase of 4.27%[172] - The company's main business revenue reached 149.981 billion yuan, a year-on-year increase of 6.91%, with a gross profit of 12.049 billion yuan, a year-on-year increase of 10.48%[173] Business Segments and Revenue Growth - The company's pharmaceutical industry self-produced and OEM business sales revenue reached 2.476 billion yuan[4] - The company's total agency brand promotion business (CSO) sales revenue reached 19.584 billion yuan, a year-on-year increase of 52.45%[5] - The company's pharmaceutical total agency brand promotion business sales revenue reached 10.696 billion yuan, a year-on-year increase of 60.82%[5] - The company's medical device total agency brand promotion business sales revenue reached 8.888 billion yuan, a year-on-year increase of 31.44%[5] - Total agency brand promotion business revenue grew 46.01% in 2023, with a 52.45% increase in gross profit[30] - Pharmaceutical new retail business revenue increased by 10.95% in 2023[30] - Digital logistics technology and supply chain solutions revenue grew 28.45% in 2023, with a 49.44% increase in gross profit[30] - Total agency brand promotion business revenue reached 19.584 billion yuan, a year-on-year increase of 46.01%[40] - Pharmaceutical new retail business revenue increased by 10.95% year-on-year[40] - Digital logistics technology and supply chain solutions revenue increased by 28.45% year-on-year[40] - Total agency brand promotion business (CSO) achieved sales revenue of 19.584 billion yuan, a year-on-year increase of 46.01%, with a gross profit of 2.789 billion yuan, up 52.45% year-on-year[43] - Pharmaceutical total agency brand promotion business achieved sales revenue of 10.696 billion yuan, a year-on-year increase of 60.82%, with a gross profit of 2.267 billion yuan, up 54.83% year-on-year[43] - Medical device total agency brand promotion business achieved sales revenue of 8.888 billion yuan, a year-on-year increase of 31.44%, with a gross profit of 522 million yuan, up 42.91% year-on-year[44] - Pharmaceutical industry self-production and OEM business achieved sales revenue of 2.476 billion yuan, with a gross profit margin of 23.84% and a gross profit of 590 million yuan[45] - JiuXin Traditional Chinese Medicine Group achieved self-production sales revenue of 1.2 billion yuan, with a gross profit margin of 25.6% and a gross profit of 307 million yuan[46] - Beijing Jingfeng Pharmaceutical Group achieved revenue of 466 million yuan, with 150+ products in production and 8 drugs passing consistency evaluation[46] - The company introduced 98 new high-quality products, including 2 with sales exceeding 100 million yuan and 10 with sales exceeding 10 million yuan[43] - The company completed the upgrade of the "Quanqing Health" brand and implemented the full-case brand upgrade for Kefei[43] - The company focused on developing large surgical, cardiovascular intervention, and IVD national platform distribution businesses, optimizing logistics systems and digital platforms[44] - The company produced 36,234 batches of traceable herbal pieces, with a total annual output of 8,991.44 tons, achieving full traceability in the herbal medicine supply chain[46] - Product sales revenue reached 1.882 billion yuan, with Jiuxin Traditional Chinese Medicine focusing on high-quality and safe products, offering a wide range of categories including precious herbs, fine drinks, and formula drinks[47] - The company has obtained 10 MAH Class II product registration certificates and 25 Class I product filing certificates, with 173 OEM medical device specifications and 424 drug OEM specifications, enhancing product competitiveness through self-developed and OEM products[47] - The "Wan Dian Jia Meng" (10,000 Store Franchise) plan has achieved significant progress, with 21,192 direct and franchise pharmacies by the end of Q1 2024, covering 31 provinces and 293 cities, and a target of over 30,000 stores by 2025[49] - Franchise pharmacy sales revenue reached 3.48 billion yuan, an 83.25% year-on-year increase, with 3,900 professional pharmacies, dual-channel pharmacies, and hospital-side stores, including 3.3 billion yuan in prescription outflow revenue[49] - B2C e-commerce total agency and sales business achieved 1.215 billion yuan in revenue, a 26.8% year-on-year growth, with rapid expansion on new e-commerce platforms like Douyin and Kuaishou[50] - The company's B2B e-commerce terminal sales channel generated 17.326 billion yuan in revenue, with the Yaojiujiu B2B platform achieving 11.241 billion yuan in self-operated transactions and covering 99% of administrative regions[51] - Retail e-commerce platform business revenue reached 6.085 billion yuan, an 11.47% year-on-year increase, with sales to JD.com and Alibaba's self-operated platforms exceeding 4.24 billion yuan, a 16.69% increase[52] - The company's logistics Bb/BC integrated warehousing and distribution system supports efficient supply chain logistics, enabling "zero inventory" for online and offline customers and sharing 100,000 product specifications[52] - The company has completed the "Bb/BC integrated warehousing and distribution" logistics service system, covering 6 "BC integrated warehouses" in Hubei, Shanghai, Guangdong, Beijing, Tianjin, and Zhejiang, and has upgraded 24 logistics centers to "Bb integrated" operations across 24 provinces[53] - The "Bb integrated project" was recognized as a leading case in digital transformation by the China Listed Companies Association and the "2023 Digital Economy Development Typical Case" by the Securities Daily[53] - The company launched the "New Medical" strategy, targeting the 321,000 clinics/outpatient departments in China, aiming to provide integrated supply chain and operational services to enhance terminal control[56] - The internet medical business achieved revenue of 156 million yuan in the reporting period, with 31 target hospitals connected to the prescription transfer platform[57] - The company is advancing the REITs project, planning to use 3.3 million square meters of pharmaceutical logistics assets as underlying assets, with the first batch of assets being the Wuhan logistics center, covering 172,000 square meters[59] - The company's digital transformation strategy has established a comprehensive digital platform, including ERP, logistics, and financial systems, supporting multiple business scenarios such as retail, new medical, and pharmaceutical distribution[61] - The company's financial shared cloud platform and "Bb integrated project" were selected as digital transformation典型案例 by the China Listed Companies Association in 2022 and 2023, respectively[61] - The company's "Bb/BC integrated warehousing and distribution project" was recognized as a "2023 Digital Economy Development Typical Case" by the Securities Daily[61] - The company's digital transformation projects, including the orthopedic smart service platform and retail digital operation platform, have been optimized and implemented[61] - The company aims to transition from a traditional pharmaceutical commercial enterprise to a technology-driven platform service provider through digital transformation[61] - The company's revenue from hospital markets reached 54.139 billion yuan, a year-on-year increase of 11.32%, with 268,600 medical institutions covered[62] - Revenue from tiered hospitals was 38.751 billion yuan, up 9.41% year-on-year, covering over 80% of tiered hospitals nationwide[62] - Revenue from primary medical institutions was 7.425 billion yuan, a year-on-year increase of 21.33%, covering over 60% of community health centers and township hospitals[63] - Revenue from private medical institutions was 7.963 billion yuan, up 12.19% year-on-year, serving major private medical groups[63] - The medical device segment achieved sales revenue of 32.815 billion yuan, a year-on-year increase of 11.66%, with 247,500 product specifications[63] - The company's orthopedic Chang'e intelligent service platform was completed, enhancing data service capabilities in the medical device field[64] - The traditional Chinese medicine (TCM) segment achieved sales revenue of 4.2 billion yuan, a year-on-year increase of 14.02%, with a gross profit of 776 million yuan[65] - The TCM segment covers 31 provinces and has established over 30 TCM production bases, with 40 varieties on the quality traceability platform[65] - The company partnered with leading domestic and foreign pharmaceutical companies, including Huarun Sanjiu, Yangtze River Pharmaceutical, and Novo Nordisk, to provide full-chain digital services[66] - Collaborations with medical device companies such as Mindray, MicroPort, and Philips enabled rapid supply to terminal markets through B2B/B2C/O2O platforms[66] - The company signed a strategic cooperation agreement with Johnson & Johnson, covering surgical, orthopedic, and interventional solutions, with a total value of nearly $500 million[67] - The company's logistics system for the "i Maotai" digital marketing platform achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million[68] - The company's logistics subsidiary, Jiuzhou Logistics, was recognized as one of Maotai Group's 23 strategic suppliers, standing out from over 2,000 suppliers[68] - The company's BC integrated warehouse in Hangzhou achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million, while the Tianjin warehouse achieved a peak daily order volume of 20,000 and a peak monthly order volume of 350,000[68] - The company's logistics subsidiary, Jiuzhou Cloud Intelligence, completed a large-scale modern high-end intelligent pharmaceutical warehousing and logistics center project for Shandong Yiyang Health Group[69] - The company signed a memorandum of cooperation with Vietnam Airlines Logistics and Vietnam International Service and Trade Investment to collaborate on logistics information technology and supply chain solutions[70] - The company held the "2023 Jiuzhoutong Financial Institutions Seminar," inviting 32 major financial institutions to discuss future cooperation directions, including expanding credit lines and innovating credit products[71] - The company formed a joint venture, Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd., to promote the development of the pharmaceutical supply chain industry in Hubei Province[73] - The company signed a strategic cooperation agreement with Tencent Health to upgrade digital management services, financial payment services, and business intelligence services[74] - The company established a joint artificial intelligence laboratory with Peking University Wuhan Artificial Intelligence Research Institute to enhance digital management and intelligent supply chain systems[74] - The company donated a total of over 3.4 million yuan to support education in 2023, including the construction of the Egret Kindergarten in Ulanhot, Inner Mongolia[75] - The company's 2022 ESG report was rated "A" by Wind ESG and ranked 2nd in the pharmaceutical business category in the 2023 Huazheng ESG rating[75] - The company donated automatic external defibrillators worth over 180,000 yuan to the Red Cross Society of Yingcheng City, Hubei Province, installed in 12 public places with high foot traffic[75] - The company actively participated in disaster relief efforts, organizing donations for the July 2023 floods in Beijing-Tianjin-Hebei and the December 2023 earthquake in Gansu[75] - The company was awarded the "Charitable Donation Enterprise" honor at the first Hubei Charity Awards in September 2023[75] - The "Opinions of the CPC Central Committee and the State Council on Promoting the Development and Growth of the Private Economy" (31 measures) was issued in July 2023, providing strong policy support for private enterprises like the company[76] - In November 2023, eight government departments jointly issued the "Notice on Strengthening Financial Support Measures to Promote the Development and Growth of the Private Economy", proposing 25 specific measures to support private enterprises[79] - The company, as a leading private enterprise in the pharmaceutical distribution industry, will benefit from the financial support policies, which will reduce financing costs and expand financing channels[80] - By 2025, the national and provincial centralized drug procurement is expected to cover more than 500 varieties[81] - The company's sales revenue in public hospitals has achieved a compound annual growth rate of 10.58% over the past three years, with the number of effective customers rapidly increasing to 13,800[85] - Over 70% of the company's existing business is in pharmacies and third-tier markets, benefiting from the outflow of hospital prescriptions and the flow of chronic disease medications to third-tier markets[85] - The company has actively promoted real-world data research on innovative drugs in private hospitals, fostering collaboration opportunities with innovative drug companies[85] - The "dual-channel" policy has been implemented nationwide, covering 2,612 drugs, with reimbursement ratios mostly ranging from 70% to 80%[88] - The company has expanded its business coverage in public hospitals, significantly benefiting from the centralized procurement policy[85] - The company has leveraged its supply chain advantages to secure distribution rights for centralized procurement products and opportunities for total agency promotion in the out-of-hospital market[86] - The company has been actively promoting the development of innovative drugs in private hospitals, enhancing collaboration with innovative drug companies[85] - The company has seen steady growth in sales scale in private hospitals through improved logistics management and supply chain services[85] - The company has capitalized on the expansion of the retail market due to the "dual-channel" and "outpatient coordination" policies[87] - The company has benefited from the dynamic adjustment of the number of drugs included in the "dual-channel" management, with the minimum number being 169 and the maximum being 529[88] - The number of "dual-channel" pharmacies in Shandong Province is expected to exceed 700 by the end of September 2023, with a fund payment ratio of around 70% and no less than 85% for primary medical institutions[89] - By the end of Q1 2024, the company has expanded its directly operated and franchised pharmacies to 21,192, with 3,900 specialty pharmacies, dual-channel pharmacies, and hospital-adjacent stores (including franchised stores)[91] - The company's Good Pharmacist pharmacies in Wuhan have been included in outpatient统筹 management, benefiting from policies such as "outpatient统筹," "dual-channel," and "seven unifications"[91] - The "clinic filing system" was implemented nationwide in 2023, leading to a potential rapid increase in the number of clinics in China[92] - The number of clinics in China reached 321,000 by the end of 2022, with 59,848 new clinics registered in the past year, a 75% increase year-on-year[93] - The clinic medication market in China is growing at a double-digit rate annually, with a market size approaching 200 billion yuan[93] - Jiuzhou Tong's "New Medical" strategy focuses on building a "Digital Medical + Supply Chain" industrial service platform targeting clinic customers, leveraging its strong supply chain capabilities and advanced information management systems[94] - The strategy includes a smart clinic solution combining auxiliary diagnosis systems, ERP systems, patient management systems, and doctor management systems to improve clinic operational efficiency[94] - Jiuzhou Tong aims to provide a turnkey solution for new clinics and drive business growth by integrating upstream supplier resources in specialized fields such as dentistry, medical aesthetics, and traditional Chinese medicine[94] - China's infrastructure REITs market has seen a series of supportive policies since the pilot program was officially launched in April 2020[95][96] - Key policy milestones include the "Guidelines for Public Offering of Infrastructure Securities Investment Funds (Trial)" in August 2020 and the "14th Five-Year Plan" in March 2021, which emphasized the healthy development of infrastructure REITs[97] - The "Notice on Further Improving the Pilot Work of Infrastructure REITs" in July 2021 highlighted the importance of project quality and long-term healthy development of infrastructure REITs[97] - In January 2022, the Ministry of Finance and the State Taxation Administration introduced tax incentives for REITs, allowing deferred taxation on asset transactions or equity acquisitions during the establishment phase[97] - The "Opinions on Further Revitalizing Existing Assets and Expanding Effective Investment" in May 2022 identified key areas for revitalizing existing assets, including infrastructure projects with large scale, good current returns, or growth potential[97] - The "Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035)" in December 2022 proposed the orderly development of infrastructure REITs to form a virtuous cycle between existing assets and new investments[98] - The total scale of infrastructure REITs in China reached 115.6 billion yuan, including 110.5 billion yuan from initial projects and 5.1 billion yuan from expansion projects[101] - The company has approximately 3.3 million square meters of pharmaceutical logistics storage assets and supporting facilities available for REITs issuance[102] - The Chinese government has introduced multiple policies to support the development of REITs, including expanding the scale of REITs issuance and encouraging private investment[99][100][101] - The company's REITs issuance is expected to provide significant equity-based funding, supporting rapid business development[102] - The Chinese government has issued policies to promote the high-quality development of the REITs market,

（2023 年度） 九州通医药集团股份有限公司 致投资者的一封信 敬启者： 春和景明，万物竞生。"高质量发展"是今年两会的热门词，以新质生产力更好地推动 高质量发展已成为社会的普遍共识。过去的一年，是中国改革开放 45 周年，是国内经济疫 后重生的第一年，也是公司持续贯彻高质量发展理念取得丰硕成果的一年。 在诸多变局不确定的大背景下，公司坚持高质量发展理念，不再片面追求销售收入规 模的扩张，注重经营管理质量的提升，经营性利润、经营性现金流、应收账款期限、资金 周转率和财务费用等各项指标均取得了良好的表现，公司的发展更加稳健、更加健康、更 加可持续。 过去的一年，我们全力拓展高质量业务，盈利能力不断提升。公司营业收入再创历史 新高，达到 1,501.40 亿元，较上年同期增长 6.92%；扣非归母净利润达 19.60 亿元，较上年 同期增长 13.06%，扣非归母净利润的增长快于营业收入的增长；经营活动现金流再创新 高，全年净额达 47.48 亿元，较上年同期增长 19.10%。在行业的支付环境没有明显改善的 情况下，公司的应收账款周转天数为 63 天，比上年缩短 6 天；公司资金周转天数为 80 天， 比上年 ...

九州通医药集团股份有限公司 股东会议事规则 第一章 总则 第一条 为维护全体股东的合法权益，规范公司股东会的召开和表决程序，保 证股东会依法行使职权，根据《公司法》《上市公司股东大会规则》《上市公司治理 准则》等法律、行政法规、部门规章、规范性文件及《公司章程》的规定，制定本 规则。 第二条 公司董事会应当切实履行职责，认真、按时召集、组织股东会。公司 全体董事应当勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。 年度股东会每年召开一次，应当于上一会计年度结束后的六个月内举行。 临时股东会不定期召开，出现《公司法》第一百一十三条规定的应当召开临时 股东会的情形时，临时股东会应当在两个月内召开。 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证券监督管理 委员会（以下简称"中国证监会"）派出机构和上海证券交易所（以下简称"上交 所"），说明原因并公告。 第五条 公司召开股东会，应当聘请律师对以下问题出具法律意见并公告： （一）会议的召集、召开程序是否符合法律、行政法规、《公司章程》的规定； （二 ...

九州通医药集团股份有限公司 募集资金管理办法 （2024年4月修订） 第一章 总则 第一条 为了规范九州通医药集团股份有限公司（以下简称"公司"）募集资 金的使用与管理，提高募集资金使用效益，保护投资者的合法权益，根据《中华 人民共和国公司法》、《中华人民共和国证券法》、《首次公开发行股票并上市管理 办法》、《上市公司证券发行管理办法》、《关于前次募集资金使用情况报告的规 定》、《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》、 《上海证券交易所股票上市规则》和《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规和规范性文件的规定，结合公司实际情况，特 制定《九州通医药集团股份有限公司募集资金管理办法》（以下简称"本办法"）。 第二条 本办法所称募集资金是指公司通过公开发行证券（包括首次公开发 行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券等） 以及非公开发行证券向投资者募集的资金，但不包括公司实施股权激励计划募集 的资金。 第三条 公司董事会应建立募集资金存储、使用和管理的内部控制制度，对 募集资金存储、使用、变更、监督和责任追究等内容进行明确规 ...